AlphaGrep UK’s Cytokinetics CYTK Stock Holding History

AlphaGrep UK’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-3,343	Closed	-$285K	–	797
2026 Q2	$285K	Buy	+3,343	New	+$240K	0.08%	502

Other funds holding CYTK

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

AlphaGrep UK's CYTK Position: Q3 2026 in Review

AlphaGrep UK sold out of Cytokinetics (CYTK) in Q3 2026, closing a stake of 3,343 shares — an estimated $285K sold.

AlphaGrep UK first reported a position in CYTK in Q2 2026 and held it in 1 quarter. The position peaked at $285K in Q2 2026. 348 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

AlphaGrep UK reported no remaining Cytokinetics position as of Q3 2026 after selling out during the quarter.
AlphaGrep UK sold 3,343 Cytokinetics shares in Q3 2026, an estimated $285K.
AlphaGrep UK first reported a position in Cytokinetics in Q2 2026 and held it in 1 quarter.
AlphaGrep UK's Cytokinetics position peaked at $285K in Q2 2026.
348 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.